Objective:Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor(CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells,especially the lower incidence rate of severe...Objective:Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor(CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells,especially the lower incidence rate of severe adverse events.However,the median progression-free survival(mPFS)of 4-1BB-based product Kymriah was shorter than that of CD28-based Yescarta(2.9 months vs.5.9 months),suggesting that Kymriah was limited in the long-term efficacy.Thus,a safe and durable 4-1BB-based CD19 CAR-T needs to be developed.Methods:We designed a CD19-targeted CAR-T(named as IM19)which consisted of an FMC63 scFv,4-1BB and CD3ζintracellular domain and was manufactured into a memory T-enriched formulation.A phase I/II clinical trial was launched to evaluate the clinical outcomes of IM19 in relapsed or refractory(r/r)B cell non-Hodgkin lymphoma(B-NHL).Dose-escalation investigation(at a dose of 5×10^(5)/kg,1×10^(6)/kg and 3×106/kg)was performed in 22 r/r B-NHL patients.All patients received a single infusion of IM19 after 3-day conditional regimen.Results:At month 3,the overall response rate(ORR)was 59.1%,the complete response rate(CRR)was 50.0%.The mPFS was 6 months and the 1-year overall survival rate was 77.8%.Cytokine release syndrome(CRS)occurred in 13 patients(59.1%),with 54.5%of grade 1−2 CRS.Only one patient(4.5%)experienced grade 3 CRS and grade 3 neurotoxicity.Conclusions:These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T,IM19,which is promising for further development and clinical investigation.展开更多
Bacillus velezensis M3-1 strain isolated from the sediment of Myriophyllum aquatium con-structedwetlandswas found to efficiently convert NO_(3)^(-)-N to NO_(2)^(−)-N,and the requirements for carbon source additionwere...Bacillus velezensis M3-1 strain isolated from the sediment of Myriophyllum aquatium con-structedwetlandswas found to efficiently convert NO_(3)^(-)-N to NO_(2)^(−)-N,and the requirements for carbon source additionwere not very rigorous.Thiswork demonstrates,for the first time,the feasibility of using the synergy of anammox and Bacillus velezensis M3-1 microorganisms for nitrogen removal.In this study,the possibility of M3-1 that converted NO_(3)^(−)-N produced by anammox to NO_(2)^(−)-N was verified in an anaerobic reactor.The NO_(3)^(−)-N reduction ability of M3-1 and denitrifying bacteria in coupling system was investigated under different C/N conditions,and it was found that M3-1 used carbon sources preferentially over denitrifying bacteria.By adjusting the ratio of NH4+-N to NO_(2)^(−)-N,it was found that the NO_(2)^(−)-N con-verted from NO_(3)^(−)-N by M3-1 participated in the original anammox.The nitrogen removal efficacy(NRE)of the coupled system was increased by 12.1%,compared to the control group anammox system at C/N=2:1.Functional gene indicated that itmight be a nitrate reducing bacterium.This study shows that the nitrate reduction rate achieved by the Bacillus velezensis M3-1 can be high enough for removing nitrate produced by anammox process,which would enable improve nitrogen removal from wastewater.展开更多
Pancreatic ductal adenocarcinoma(PDAC)is currently the fourth most common cause of cancer-related deaths in the United States.It has a poor prognosis and remains a difficulty to treat malignancy.Over the past several ...Pancreatic ductal adenocarcinoma(PDAC)is currently the fourth most common cause of cancer-related deaths in the United States.It has a poor prognosis and remains a difficulty to treat malignancy.Over the past several decades,significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment.In recent years,the measurement of serum carbohydrate antigen 19-9(CA 19-9)has become one of the most validated and extensively used tumour biomarkers for PDAC.In particular,serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment.However,despite its clinical relevance,the implications on diagnosis or accurately predicting tumour resectability,and monitoring disease symptoms in PDAC patients remains limited.This current review highlights the recent updates on the applicability of CA 19-9,its exploitation,and challenges in predicting the treatment efficacy and responses in PDAC patients.展开更多
基金supported by the Beijing Natural Science Foundation (No. 7202026)Capital’s Funds for Health Improvement and Research (No. 2020-2Z-2157)
文摘Objective:Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor(CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells,especially the lower incidence rate of severe adverse events.However,the median progression-free survival(mPFS)of 4-1BB-based product Kymriah was shorter than that of CD28-based Yescarta(2.9 months vs.5.9 months),suggesting that Kymriah was limited in the long-term efficacy.Thus,a safe and durable 4-1BB-based CD19 CAR-T needs to be developed.Methods:We designed a CD19-targeted CAR-T(named as IM19)which consisted of an FMC63 scFv,4-1BB and CD3ζintracellular domain and was manufactured into a memory T-enriched formulation.A phase I/II clinical trial was launched to evaluate the clinical outcomes of IM19 in relapsed or refractory(r/r)B cell non-Hodgkin lymphoma(B-NHL).Dose-escalation investigation(at a dose of 5×10^(5)/kg,1×10^(6)/kg and 3×106/kg)was performed in 22 r/r B-NHL patients.All patients received a single infusion of IM19 after 3-day conditional regimen.Results:At month 3,the overall response rate(ORR)was 59.1%,the complete response rate(CRR)was 50.0%.The mPFS was 6 months and the 1-year overall survival rate was 77.8%.Cytokine release syndrome(CRS)occurred in 13 patients(59.1%),with 54.5%of grade 1−2 CRS.Only one patient(4.5%)experienced grade 3 CRS and grade 3 neurotoxicity.Conclusions:These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T,IM19,which is promising for further development and clinical investigation.
基金supported by the National Natural Sci-ence Foundation of China(Nos.42177099,91951108,and 21976197)the Knowledge Innovation Program of Shenzhen(No.JSGG20191129112812329),and the CAS International Part-nership Program(No.121311KYSB20200017)the special fund of State Key Joint Laboratory of Environment Simula-tion and Pollution Control(No.21Z02ESPCR).
文摘Bacillus velezensis M3-1 strain isolated from the sediment of Myriophyllum aquatium con-structedwetlandswas found to efficiently convert NO_(3)^(-)-N to NO_(2)^(−)-N,and the requirements for carbon source additionwere not very rigorous.Thiswork demonstrates,for the first time,the feasibility of using the synergy of anammox and Bacillus velezensis M3-1 microorganisms for nitrogen removal.In this study,the possibility of M3-1 that converted NO_(3)^(−)-N produced by anammox to NO_(2)^(−)-N was verified in an anaerobic reactor.The NO_(3)^(−)-N reduction ability of M3-1 and denitrifying bacteria in coupling system was investigated under different C/N conditions,and it was found that M3-1 used carbon sources preferentially over denitrifying bacteria.By adjusting the ratio of NH4+-N to NO_(2)^(−)-N,it was found that the NO_(2)^(−)-N con-verted from NO_(3)^(−)-N by M3-1 participated in the original anammox.The nitrogen removal efficacy(NRE)of the coupled system was increased by 12.1%,compared to the control group anammox system at C/N=2:1.Functional gene indicated that itmight be a nitrate reducing bacterium.This study shows that the nitrate reduction rate achieved by the Bacillus velezensis M3-1 can be high enough for removing nitrate produced by anammox process,which would enable improve nitrogen removal from wastewater.
文摘Pancreatic ductal adenocarcinoma(PDAC)is currently the fourth most common cause of cancer-related deaths in the United States.It has a poor prognosis and remains a difficulty to treat malignancy.Over the past several decades,significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment.In recent years,the measurement of serum carbohydrate antigen 19-9(CA 19-9)has become one of the most validated and extensively used tumour biomarkers for PDAC.In particular,serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment.However,despite its clinical relevance,the implications on diagnosis or accurately predicting tumour resectability,and monitoring disease symptoms in PDAC patients remains limited.This current review highlights the recent updates on the applicability of CA 19-9,its exploitation,and challenges in predicting the treatment efficacy and responses in PDAC patients.
